The Rheumatologist reports on the “State of the Art: Lupus—The Future Is Now” session led by Mary K. Crow, MD, Physician-in-Chief Emerita at HSS, at the virtual American College of Rheumatology (ACR) annual meeting.

Dr. Crow explained there is a renewed hope for new treatment options for systemic lupus erythematosus (SLE) based on recent positive trial results. Focal points for new lupus therapies include combination therapies that target the interferon pathway, autoantibody production and effector macrophages that all hold more promise than current treatment approaches. Further analysis of genetic variants that are associated with an increased risk for lupus also could help identify molecular pathways that contribute to disease development, noted Dr. Crow.

Read the full article at the-rheumatologist.org. 

Additional coverage: the-rheumatologist.org